EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The mediating role of plasma glial fibrillary acidic protein in amyloid and tau pathology in Down's syndrome

Anna H Boerwinkle, Julie K Wisch iD, Benjamin L Handen, Elizabeth Head, Mark Mapstone, Michael S Rafii, Sid E O'Bryant, Sharon J Krinsky-McHale, Florence Lai, H Diana Rosas, Shahid Zaman, Ira T Lott und 6 weitere

Alzheimer's & Dementia · 2025

DOI: 10.1002/alz.14359 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2025. Verfasst von Anna H Boerwinkle und 17 weiteren Autor:innen. Beteiligte Einrichtung: McGovern Medical School, University of Texas in Houston, Houston, Texas, USA. Hauptthemen laut MEDLINE: Glial Fibrillary Acidic Protein, Down Syndrome, tau Proteins, Alzheimer Disease. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, National Institute on Aging.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Development of Alzheimer's disease (AD) pathology in Down's syndrome (DS) occurs within a compressed timeline compared to sporadic or other genetic forms of AD. METHODS Plasma glial fibrillary acidic protein (GFAP) and plasma pTau‐217 levels were compared by AD pathophysiology (amyloid (A+) and tau (T+) positron emission tomography [PET]) in persons with DS ( N = 348) and sibling controls ( N = 42). Plasma GFAP, plasma pTau‐217, amyloid‐PET, and tau‐PET levels were compared with regard to estimated years to onset of clinical symptoms (52.5 years old). We evaluated if plasma GFAP mediated the relationship between amyloid PET and plasma pTau‐217 or tau PET. RESULTS Plasma GFAP, a measure of astrogliosis, was elevated in A+/T‐ and A+/T+ individuals with DS. Plasma pTau‐217 was elevated in A+/T+ individuals with DS. GFAP partially mediated the relationship between amyloid‐PET and tau‐PET (15.3%) and amyloid‐PET and plasma pTau‐217 (42.1%). DISCUSSION Astrogliosis is a key component in the advancement of preclinical AD pathophysiology in DS. Highlights Amyloid may be a necessary precursor for stimulating astrocytes. Astrogliosis may play a key role in modifications to tau phosphorylation. Targeting neuroinflammation may only aid amyloid positive individuals. Alzheimer's disease timecourse is compressed in individuals with Down's syndrome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glial Fibrillary Acidic ProteinDown Syndrometau ProteinsAlzheimer DiseaseAmyloid beta-PeptidesHumansFemaleMalePositron-Emission TomographyMiddle AgedAdultAgedBiomarkersBrainGliosis

Stichwörter der Autor:innen

Alzheimer's diseaseDown's syndromebiomarkersplasma

Substanzen

Glial Fibrillary Acidic Proteintau ProteinsGFAP protein, humanAmyloid beta-PeptidesBiomarkers

Autor:innen und Institutionen

  • McGovern Medical School, University of Texas in Houston, Houston, Texas, USA.
  • Department of Neurology, Washington University in St. Louis, St. Louis, Missouri, USA.
  • Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Department of Pathology, Gillespie Neuroscience Research Facility, University of California - Irvine, Irvine, California, USA.
  • Department of Neurology, University of California Irvine School of Medicine, Orange, California, USA.
  • Alzheimer's Therapeutic Research Institute, Keck School of Medicine of USC, Los Angeles, California, USA.

ORCID-Profile: Julie K Wisch

Förderung

  • NIA NIH HHS
  • National Institute on Aging

Zitieren

APA

Boerwinkle, A. H., Wisch, J. K., Handen, B. L., Head, E., Mapstone, M., Rafii, M. S., O'Bryant, S. E., Krinsky-McHale, S. J., Lai, F., Rosas, H. D., Zaman, S., Lott, I. T., Tudorascu, D., Zammit, M., Brickman, A. M., Lee, J. H., Ances, B. M., & Alzheimer's Biomarker Consortium‐Down Syndrome (2025). The mediating role of plasma glial fibrillary acidic protein in amyloid and tau pathology in Down's syndrome. Alzheimer's & Dementia. https://doi.org/10.1002/alz.14359

Vancouver

Boerwinkle AH, Wisch JK, Handen BL, Head E, Mapstone M, Rafii MS, et al. The mediating role of plasma glial fibrillary acidic protein in amyloid and tau pathology in Down's syndrome. Alzheimer's & Dementia. 2025. doi:10.1002/alz.14359

BibTeX
@article{Boerwinkle2025,
  author = {Boerwinkle, Anna H and Wisch, Julie K and Handen, Benjamin L and Head, Elizabeth and Mapstone, Mark and Rafii, Michael S and O'Bryant, Sid E and Krinsky-McHale, Sharon J and Lai, Florence and Rosas, H Diana and Zaman, Shahid and Lott, Ira T and Tudorascu, Dana and Zammit, Matthew and Brickman, Adam M and Lee, Joseph H and Ances, Beau M and Alzheimer's Biomarker Consortium‐Down Syndrome, Alzheimer's Biomarker Consortium‐Down Syndrome},
  title = {The mediating role of plasma glial fibrillary acidic protein in amyloid and tau pathology in Down's syndrome},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  doi = {10.1002/alz.14359}
}
Kostenlos starten →